Developing disease modifying alkaline phosphatase therapeutics for Acute Kidney Injury and Inflammatory Bowel Disease.

AM–Pharma is a biopharmaceutical company developing proprietary recombinant human alkaline phosphatase therapeutics, which have the potential to transform the treatment prospects for patients with chronic or life-threatening inflammatory diseases.

Disease modifying therapies
AM-Pharma discovered that alkaline phosphatase can protect organs against inflammation and tissue damage. While this enzyme is found in many cells of the body, it is present at reduced levels in certain diseases including Acute Kidney Injury and Ulcerative Colitis.

The Company’s proprietary therapeutics are disease modifying therapies and have the potential to be “first-in-class” medicines.
Read more.

Lead programs and partnering
AM-Pharma will be seeking partnerships for its lead programs in Acute Kidney Injury and Inflammatory Bowel Disease.
Read more.

Market Need

Acute Kidney Injury is an acute inflammation of the kidney, which results in kidney damage and a rapid loss of kidney function and often leads to dialysis. Depending on the severity of kidney failure, the mortality rate is as high as 80%.There are currently no approved drugs for disease treatment.
Read more.

Inflammatory Bowel Disease is a group of inflammatory conditions of the colon and small intestine, The major types include Crohn's disease and Ulcerative Colitis. There are two biologics  approved for treating ulcerative colitis, but there remains a clear need for a therapy that is both safe, efficacious over time and convenient to use.

Read more.

Latest News

January 20 2015
AM-Pharma starts Adaptive Phase II trial of recAP in Acute Kidney Injury
Read more.

December 2 2014
Preclinical data published on AM-Pharma’s recAP to treat ultra rare disease Hypophosphatasia
Read more.